{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:17Z","timestamp":1787664257124,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s11899-996-0005-8","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T01:11:15Z","timestamp":1179969075000},"page":"171-179","source":"Crossref","is-referenced-by-count":12,"title":["Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults"],"prefix":"10.1007","volume":"1","author":[{"given":"Heather","family":"Landau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10\u201330.","journal-title":"CA Cancer J Clin"},{"key":"5_CR2","first-page":"40","volume":"3","author":"N Lamanna","year":"2004","unstructured":"Lamanna N, Weiss M: Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep 2004, 3:40\u201346.","journal-title":"Curr Hematol Rep"},{"key":"5_CR3","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Gokbuget N, Ottmann O, et al.: Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2002, 162\u2013192.","DOI":"10.1182\/asheducation-2002.1.162"},{"key":"5_CR4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"CH Pui","year":"2004","unstructured":"Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535\u20131548.","journal-title":"N Engl J Med"},{"key":"5_CR5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664","volume":"85","author":"C Soussain","year":"1995","unstructured":"Soussain C, Patte C, Ostronoff M, et al.: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664\u2013674.","journal-title":"Blood"},{"key":"5_CR6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","volume":"17","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Cortes J, O\u2019Brien S et al.: Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461\u20132470.","journal-title":"J Clin Oncol"},{"key":"5_CR7","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","volume":"19","author":"EJ Lee","year":"2001","unstructured":"Lee EJ, Petroni GR, Schiffer CA et al.: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001, 19:4014\u20134022.","journal-title":"J Clin Oncol"},{"key":"5_CR8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079\u20131082.","journal-title":"Science"},{"key":"5_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11912-005-0058-1","volume":"7","author":"JM Scandura","year":"2005","unstructured":"Scandura JM: Advances in the molecular genetics of acute leukemia. Curr Oncol Rep 2005, 7:323\u2013332.","journal-title":"Curr Oncol Rep"},{"key":"5_CR10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403673","volume":"19","author":"MJ Sutcliffe","year":"2005","unstructured":"Sutcliffe MJ, Shuster JJ, Sather HN, et al.: High concordance from independent studies by the Children\u2019s Cancer Group (CCG) and Pediatric Oncolog y Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children\u2019s Oncolog y Group (COG) initiative. Leukemia 2005, 19:734\u2013740.","journal-title":"Leukemia"},{"key":"5_CR11","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood.V87.8.3135.bloodjournal8783135","volume":"87","author":"Groupe Fran\u00e7ais de Cytog\u2019en\u2019etique H\u2019ematologique","year":"1996","unstructured":"Groupe Fran\u00e7ais de Cytog\u2019en\u2019etique H\u2019ematologique:Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Group Fran\u00e7ais de Cytog\u2019en\u2019etique H\u2019ematologique. Blood 1996, 87:3135\u20133142.This paper demonstrates karyotypic differences between adult and childhood ALL and the prognostic implications of karyotypes.","journal-title":"Blood"},{"key":"5_CR12","unstructured":"World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001."},{"key":"5_CR13","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","volume":"18","author":"JL Hecht","year":"2000","unstructured":"Hecht JL, Aster JC: Molecular biology of Burkitt\u2019s lymphoma. J Clin Oncol 2000, 18:3707\u20133721.","journal-title":"J Clin Oncol"},{"key":"5_CR14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269\u2013271.This article reports common activating mutations of NOTCH1 and presents a rationale for a new clinical strateg y for the treatment of T-cell ALL.","journal-title":"Science"},{"key":"5_CR15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","volume":"342","author":"M Arico","year":"2000","unstructured":"Arico M, Valsecchi MG, Camitta B, et al.: Outcome of treatment in children with Philadelphia chromosome -positive acute lymphoblastic leukemia. N Engl J Med 2000, 342:998\u20131006.","journal-title":"N Engl J Med"},{"key":"5_CR16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.leu.2400959","volume":"12","author":"JM Chessells","year":"1998","unstructured":"Chessells JM, Hall E, Prentice HG, et al.: The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998, 12:463\u2013473.","journal-title":"Leukemia"},{"key":"5_CR17","first-page":"85","volume":"23","author":"R Ohno","year":"1993","unstructured":"Ohno R: Current progress in the treatment of adult acute leukemia in Japan. Jpn J Clin Oncol 1993, 23:85\u201397.","journal-title":"Jpn J Clin Oncol"},{"key":"5_CR18","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1200\/JCO.2005.07.048","volume":"23","author":"MA Weiss","year":"2005","unstructured":"Weiss MA, Heffner L, Lamanna N, et al., for the ALL-4 Consortium: A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine\/prednisone-based regimen as induction therapy for adult patients with ALL [abstract]. J Clin Oncol (Meeting Abstracts) 2005, 23:6516.","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"5_CR19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1988.6.6.1014","volume":"6","author":"J Gaynor","year":"1988","unstructured":"Gaynor J, Chapman D, Little C, et al.: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988, 6:1014\u20131030.One of two \"classic\" papers on prognostic factors in adult ALL.","journal-title":"J Clin Oncol"},{"key":"5_CR20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","volume":"71","author":"D Hoelzer","year":"1988","unstructured":"Hoelzer D, Thiel E, Loffler H, et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123\u2013131. One of two \"classic\" papers on prognostic factors in adult ALL.","journal-title":"Blood"},{"key":"5_CR21","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V84.5.1603.bloodjournal8451603","volume":"84","author":"C Boucheix","year":"1994","unstructured":"Boucheix C, David B, Sebban C et al.: Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994, 84:1603\u20131612.","journal-title":"Blood"},{"key":"5_CR22","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","volume":"21","author":"ML Boer Den","year":"2003","unstructured":"Den Boer ML, Harms DO, Pieters R, et al.: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21:3262\u20133268.","journal-title":"J Clin Oncol"},{"key":"5_CR23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1983.1.8.462","volume":"1","author":"P Schauer","year":"1983","unstructured":"Schauer P, Arlin ZA, Mertelsmann R, et al.: Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983, 1:462\u2013470. The first major paper to demonstrate that adult ALL is a curable neoplasm.","journal-title":"J Clin Oncol"},{"key":"5_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V64.1.38.38","volume":"64","author":"D Hoelzer","year":"1984","unstructured":"Hoelzer D, Thiel E, Loffler H, et al.: Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984, 64:38\u201347.","journal-title":"Blood"},{"key":"5_CR25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547\u2013561.","journal-title":"J Clin Oncol"},{"key":"5_CR26","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","volume":"20","author":"C Linker","year":"2002","unstructured":"Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464\u20132471.","journal-title":"J Clin Oncol"},{"key":"5_CR27","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"R A Larson","year":"1995","unstructured":"Larson R A, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025\u20132037.","journal-title":"Blood"},{"key":"5_CR28","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/sj.leu.2402289","volume":"15","author":"X Thomas","year":"2001","unstructured":"Thomas X, Danaila C, Le QH, et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15:1811\u20131822.","journal-title":"Leukemia"},{"key":"5_CR29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term followup of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863\u2013871.","journal-title":"Blood"},{"key":"5_CR30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","volume":"16","author":"J Takeuchi","year":"2002","unstructured":"Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259\u20131266.","journal-title":"Leukemia"},{"key":"5_CR31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V64.1.267.267","volume":"64","author":"AJ Gottlieb","year":"1984","unstructured":"Gottlieb AJ, Weinberg V, Ellison RR, et al.: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 1984, 64:267\u2013274.","journal-title":"Blood"},{"key":"5_CR32","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.1996.14.9.2480","volume":"14","author":"M Weiss","year":"1996","unstructured":"Weiss M, Maslak P, Feldman E, et al.: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14:2480\u20132485.This article shows the efficacy of a novel approach to ALL induction therapy with high-dose mitoxantrone and cytarabine. This study led to the recently completed randomized phase III clinical trial comparing the novel regimen to a standard induction program.","journal-title":"J Clin Oncol"},{"key":"5_CR33","first-page":"64","volume":"14","author":"D Fiere","year":"1987","unstructured":"Fiere D, Extra JM, David B, et al.: Treatment of 218 adult acute lymphoblastic leukemias. Semin Oncol 1987, 14:64\u201366.","journal-title":"Semin Oncol"},{"key":"5_CR34","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2000.18.7.1508","volume":"18","author":"Y Toyoda","year":"2000","unstructured":"Toyoda Y, Manabe A, Tsuchida M, et al.: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000, 18:1508\u20131516.","journal-title":"J Clin Oncol"},{"key":"5_CR35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.leu.2401973","volume":"14","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Zimmermann M, et al.: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000, 14:2205\u20132222.","journal-title":"Leukemia"},{"key":"5_CR36","doi-asserted-by":"crossref","unstructured":"Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet 1996, 347:1783\u20131788.","DOI":"10.1016\/S0140-6736(96)91615-3"},{"issue":"Suppl 2","key":"5_CR37","first-page":"178","volume":"6","author":"PA Cassileth","year":"1992","unstructured":"Cassileth PA, Andersen JW, Bennett JM, et al.: Adult acute lymphocytic leukemia: the Eastern Cooperative Oncolog y Group experience. Leukemia 1992, 6(Suppl 2):178\u2013181.","journal-title":"Leukemia"},{"key":"5_CR38","first-page":"425","volume":"5","author":"J Cuttner","year":"1991","unstructured":"Cuttner J, Mick R, Budman DR, et al.: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia 1991, 5:425\u2013431.","journal-title":"Leukemia"},{"key":"5_CR39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1997.15.2.476","volume":"15","author":"AW Dekker","year":"1997","unstructured":"Dekker AW, van\u2019t Veer MB, Sizoo W, et al.: Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol 1997, 15:476\u2013482.","journal-title":"J Clin Oncol"},{"key":"5_CR40","first-page":"2088","volume-title":"Cancer: Principles and Practice of Oncology","author":"DA Scheinberg","year":"2005","unstructured":"Scheinberg DA, Maslak PG, Weiss MA: Acute leukemias. In Cancer: Principles and Practice of Oncology, edn 7. Edited by DeVita V T Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2005:2088\u20132116.","edition":"edn 7"},{"key":"5_CR41","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.V72.5.1784.1784","volume":"72","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Walters RS, Smith TL, et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784\u20131789.","journal-title":"Blood"},{"key":"5_CR42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.V55.2.199.199","volume":"55","author":"GA Omura","year":"1980","unstructured":"Omura GA, Moffitt S, Vogler WR, Salter MM: Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980, 55:199\u2013204.","journal-title":"Blood"},{"key":"5_CR43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2003.04.096","volume":"21","author":"B Burger","year":"2003","unstructured":"Burger B, Zimmermann M, Mann G, et al.: Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003, 21:184\u2013188.","journal-title":"J Clin Oncol"},{"key":"5_CR44","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.1994.12.12.2580","volume":"12","author":"C Sebban","year":"1994","unstructured":"Sebban C, Lepage E, Vernant JP, et al.: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994, 12:2580\u20132587.The randomized trial showed no benefit for allogeneic or autologous transplantation in first complete remission for adults with ALL.","journal-title":"J Clin Oncol"},{"key":"5_CR45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7326\/0003-4819-123-6-199509150-00006","volume":"123","author":"MJ Zhang","year":"1995","unstructured":"Zhang MJ, Hoelzer D, Horowitz MM, et al.: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med 1995, 123:428\u2013431.","journal-title":"Ann Intern Med"},{"key":"5_CR46","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357\u20132366. The best evidence to date that allogeneic transplantation improves the outcome for patients with Ph+ and high-risk ALL.","journal-title":"Blood"},{"key":"5_CR47","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.2004.07.130","volume":"22","author":"MG Kiehl","year":"2004","unstructured":"Kiehl MG, Kraut L, Schwerdtfeger R, et al.: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816\u20132825.This study found similar outcomes for patients who received matched related or unrelated allografts, potentially increasing thetransplantation options for high-risk patients.","journal-title":"J Clin Oncol"},{"key":"5_CR48","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa041469","volume":"351","author":"V Rocha","year":"2004","unstructured":"Rocha V, Labopin M, Sanz G, et al.: Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276\u20132285.","journal-title":"N Engl J Med"},{"key":"5_CR49","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa041276","volume":"351","author":"MJ Laughlin","year":"2004","unstructured":"Laughlin MJ, Eapen M, Rubinstein P, et al.: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265\u20132275.","journal-title":"N Engl J Med"},{"key":"5_CR50","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood.V87.12.5251.bloodjournal87125251","volume":"87","author":"J Brisco","year":"1996","unstructured":"Brisco J, Hughes E, Neoh SH, et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996, 87:5251\u20135256.","journal-title":"Blood"},{"key":"5_CR51","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","volume":"20","author":"FY Mortuza","year":"2002","unstructured":"Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094\u20131104.","journal-title":"J Clin Oncol"},{"key":"5_CR52","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","volume":"101","author":"MB Vidriales","year":"2003","unstructured":"Vidriales MB, Perez JJ, Lopez-Berges MC, et al.: Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101:4695\u20134700.","journal-title":"Blood"},{"key":"5_CR53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Bruggemann","year":"2006","unstructured":"Bruggemann M, Raff T, Flohr T, et al.: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116\u20131123.Although this study highlights the limitations of minimal residual disease (MRD) evaluation, it demonstrates that MRD can be an important prognostic tool in adults with ALL.","journal-title":"Blood"},{"key":"5_CR54","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965\u20131971.","journal-title":"Blood"},{"key":"5_CR55","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396\u20134407.Although the effects of imatinib are less dramatic in Ph+ ALL than in CML, the combination of imatinib and chemotherapy appears to have important clinical benefit for these patients.","journal-title":"Blood"},{"key":"5_CR56","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460\u2013466.","journal-title":"J Clin Oncol"},{"key":"5_CR57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","volume":"19","author":"KH Lee","year":"2005","unstructured":"Lee KH, Lee JH, Choi SJ, et al.: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005, 19:1509\u20131516.","journal-title":"Leukemia"},{"key":"5_CR58","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","volume":"36","author":"C Graux","year":"2004","unstructured":"Graux C, Cools J, Melotte C, et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084\u20131089.","journal-title":"Nat Genet"},{"key":"5_CR59","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","volume":"21","author":"N Boissel","year":"2003","unstructured":"Boissel N, Auclerc MF, Lheritier V, et al.: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774\u2013780.This provocative paper is the first of four recent studies indicating that young adults benefit from treatment with more aggressive \"pediatric-style\" regimens.","journal-title":"J Clin Oncol"},{"key":"5_CR60","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","volume":"18","author":"JM Bont de","year":"2004","unstructured":"de Bont JM, Holt B, Dekker AW, et al.: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004, 18:2032\u20132035.","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-996-0005-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-996-0005-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-996-0005-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T08:13:16Z","timestamp":1587543196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-996-0005-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s11899-996-0005-8","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}